Research on schizophrenia-affected rat models shows potential for #CBD to minimize many #schizophrenia symptoms
Cannabidiol (CBD) may have potential as a schizophrenia therapeutic agent. Individuals with schizophrenia exhibit decreased activity in choline acetyltransferase (ChAT) activity, an enzyme associated with cognitive functioning. In rat models mimicking schizophrenia, affected rats treated with CBD exhibited normal ChAt activity, while their untreated counterparts exhibited reduced activity.
CED Foundation Google Drive: http://bit.ly/2HHWW8E
Read Here or Download:
Effect of cannabidiol on muscarinic neurotransmission in the prefrontal cortex and hippocampus of the poly I-C rat model of schizophreniaDownload





